新辅助化疗对胃标志环细胞癌的生存结果的影响
Salvatore Sorrenti1, Silvia Malerba2,3,4, Eleonora Lori1
1Department of Surgery, "Sapienza" University of Rome, 00161 Roma, Italy.
Cancers
|July 29, 2025
概括
新辅助化疗 (NAC) 对大多数胃结环细胞癌 (GSRCC) 患者的整体存活率 (OS) 没有改善. 然而,特定的子组,特别是那些中部或远部瘤的人,可能会从NAC中受益.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 胃肠病学 胃肠病学
背景情况:
- 胃环细胞癌 (GSRCC) 是一种具有攻击性的亚型,对新辅助化疗 (NAC) 疗效的证据有限.
- 评估NAC对整体存活 (OS) 的影响对于GSRCC的治疗优化至关重要.
研究的目的:
- 评估新辅助化疗 (NAC) 对胃结环细胞癌 (GSRCC) 患者的大群总生存期 (OS) 的影响.
- 为了确定生存的预测因素,并探索在特定的患者小组中NAC的潜在益处.
主要方法:
- 对SEER数据库 (2011-2018) 的分析,其中包括978名接受治疗意图胃切除术的GSRCC患者.
- 使用卡普兰-梅尔分析和多变量考克斯回归,对接受新辅助化疗 (NAC) 和未接受化疗的患者的整体存活期 (OS) 进行比较.
- 进行了子组分析,以调查NAC与瘤位置和临床阶段的相互作用.
主要成果:
- 新辅助化疗 (NAC) 在胃结环细胞癌 (GSRCC) 患者的整体队列中没有改善整体存活率 (OS) (5年OS:39.7%与37.2%,p=0.34).
- 更糟糕的OS的独立预测因素包括较大的瘤大小,晚期,阳性节点状况和黑人种族.
- 在中部或远部胃瘤的子组中观察到NAC的显著生存益处 (p < 0.001的相互作用).
结论:
- 新辅助化疗 (NAC) 对胃结环细胞癌 (GSRCC) 患者的总体生存率 (OS) 没有改善.
- 选定的子组,特别是那些中部或远部瘤的子组,可能会从NAC中受益,这表明需要在GSRCC中个性化新辅助治疗策略.
更多相关视频
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
11.2K
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
380
相关概念视频
Cancer Survival Analysis
456
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
456
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
262
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
262
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
322
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
322
